Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Tapentadol (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 25 Jun 2013 Actual initiation date changed from May 2010 to Jun 2010 as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2011 Actual end date (April 2011) added as reported by ClinicalTrials.gov.